Clinical trials: Intravenous
Healthy Volunteers, Anti-Bacterial Agents
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
The Objectives of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single dose of N-Rephasin® SAL200 in healthy male subjects.
- Conditions
- Healthy Volunteers, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus Aureus
- Trial name
- NCT01855048
- Testing
- N-Rephasin® SAL200
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Major Surgery
Intravenous Oliceridine and Opioid-related Complications
The investigator will evaluate the side effects of oliceridine.
- Trial name
- NCT04979247
- Testing
- Oliceridine
- Where
- 3 sites in United States
- Volunteers
- 204 people
- Sponsor
- The Cleveland Clinic
Sedation
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
The purpose of this study is to evaluate the safety and efficacy of LUSEDRA (fospropofol disodium) and to determine whether a dose lower than currently approved can provide effective moderate sedation required to complete…
- Trial name
- NCT01127438
- Testing
- fospropofol disodium Subgroup 1 Lower Dose, fospropofol disodium Subgroup 1 Approved Dose, fospropofol disodium Subgroup 2 Lower Dose
- Where
- 23 sites in United States
- Volunteers
- 153 people
- Sponsor
- Eisai Inc.
Fabry Disease
PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion
Pharmacokinetic/Pharmacodynamic Study of 2 agalsidase beta Formulations in Single Dose Administered to Healthy Volunteers as intravenous infusion, at a concentration of 1 mg/kg
- Trial name
- NCT05343715
- Testing
- Agalsidase beta from Biosidus 1 mg/kg, Fabrazyme (agalsidase beta) 1 mg/kg
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Gram-Positive Bacterial Infections
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
- Trial name
- ASSURE (NCT00062647)
- Testing
- Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cumberland Pharmaceuticals
Lymphoma, Non-Hodgkin
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of…
- Trial name
- CHRONOS-4 (NCT02626455)
- Testing
- Copanlisib (BAY80-6946), Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Australia and 33 more
- Volunteers
- 551 people
- Sponsor
- Bayer
Neoplasms
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
This open-label phase I dose escalation trial, 1230.15, is the first trial with Volasertib in Japanese advanced cancer patients.
- Trial name
- NCT01348347
- Testing
- Volasertib, low dose, d1q3w, Volasertib, middle dose, d1q3w, Volasertib, high dose, d1q3w
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Hyperparathyroidism, Secondary
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males.
- Trial name
- NCT01134549
- Testing
- Etelcalcetide
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- KAI Pharmaceuticals
Chronic Cluster Headache
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.
- Trial name
- NCT02964338
- Testing
- Fremanezumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 259 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Anemia
A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous methoxy polyethylene glycolepoetin beta (Mircera) for the maintenance of hemoglobin levels in hemodialysis…
- Trial name
- CARISMA (NCT00699348)
- Testing
- Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
- Where
- 60 sites in Italy
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Infection
Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection…
- Trial name
- NCT02158442
- Testing
- Percutaneous Isolated Limb Perfusion (PILP) delivery, Timentin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Osprey Medical, Inc
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypercholesterolemia, Dyslipidemias
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
This Phase 1 study has been designed to evaluate the absolute bioavailability of PF-04950615 (RN316) in subjects with hypercholesterolemia who are not currently on lipid-lowering therapy.
- Conditions
- Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders
- Trial name
- NCT01435382
- Testing
- PF-04950615 (RN316)
- Where
- 7 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
This study is a multicenter, double-blind, study to evaluate the safety and effectiveness of treatment with LY2127399 (in addition to the standard of care treatment, methotrexate) for participants with Rheumatoid Arthritis.
- Trial name
- NCT00308282
- Testing
- LY2127399
- Where
- 14 sites in Romania
- Volunteers
- 136 people
- Sponsor
- Eli Lilly and Company
Cardiac Arrest
Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
The effectiveness of medications in cardiac arrest has been greatly debated and questioned. Historically intravenous adrenaline has been the drug of choice since 1906.
- Trial name
- PIVOT (NCT00358579)
- Testing
- Adrenaline, Vasopressin
- Where
- 4 sites in Singapore
- Volunteers
- 727 people
- Sponsor
- Singapore General Hospital
Chronic Rhinosinusitis
Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.
The purpose of this study is to compare total intravenous anesthesia to inhaled anesthesia in endoscopic sinus surgery for chronic sinusitis.
- Trial name
- NCT01214057
- Testing
- Propofol and Remifentanyl, Sevoflurane and Remifentanyl
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy
Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
The purpose of this study is to characterize and compare the concentration-time profiles and multiple dose pharmacokinetics of a 5 minute intravenous (IV) bolus of ertapenem 1 gram daily versus the standard 30 minute infusion in…
- Trial name
- NCT01148771
- Testing
- ertapenem
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Hyperglycemia
Comparative Trial Between 3 Types of Insulin Infusion Protocols
Increasing evidence from observational studies in hospitalized patients with and without diabetes indicates that hyperglycemia is a predictor of poor outcome.
- Trial name
- NCT00582309
- Testing
- Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
- Where
- 3 sites in United States
- Volunteers
- 151 people
- Sponsor
- University of New Mexico
Infectious Peritonitis
Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
This study will evaluate the pharmacokinetic properties of dalbavancin when administered as an intravenous infusion and instilled into the peritoneal space in patients who are undergoing peritoneal dialysis.
- Trial name
- NCT02940730
- Testing
- Dalbavancin via Intravenous Administration, Dalbavancin via Intraperitoneal Administration
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449163
- Testing
- Bevacizumab, Floxuridine, Irinotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.